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Diabetes type 2 and insulin resistance are the risk factors for cardiovascular disease. It is already known that atherosclerosis is an
inﬂammatory disease, and a lot of diﬀerent factors are involved in its onset. C-peptide is a cleavage product of proinsulin, an active
substance with a number of eﬀects within diﬀerent complications of diabetes. In this paper we discuss the role of C-peptide and
its eﬀects in the development of atherosclerosis in type 2 diabetic patients.
1.Introduction
C-peptide is a small 31-amino acid peptide, and it is cleaved
from proinsulin in the synthesis of insulin [1]. Proinsulin
consists of A and B chain and connecting peptide in the
middle, called C-peptide. Cleavage of proinsulin takes place
in endoplasmatic reticulum of beta pancreatic cells. In ad-
dition, C-peptide is stored in Golgi secretory granules and
is cosecreted in equimolar amounts into the blood stream
together with insulin in response to the glucose stimu-
lation [1, 2]. Amino acid sequences of C-peptide are in
diﬀerent species relatively variable. Nevertheless, C-peptide
has several conserved sequences, for example, N terminal
acidic region, glycine-rich central segment, and C-terminal
pentapeptide [3]. Despite the ﬁrst reports describing C-pep-
tide as a peptide with little or no biological activity, recent
data reports binding of radioactive labelled C-peptide on
the cell membranes [4]. Other studies show binding eﬀects
stimulating Na-K-ATPase. C-terminal pentapeptide gives
full replacement of the entire molecule, which is similar
to other peptides with hormone function like gastrin and
cholecystokinin [5, 6]. The receptor stays unknown but there
is a lot of data demonstrating C-peptide biological eﬀects by
activating diﬀerent signalling pathways, for example binding
topertussis-toxin-sensitiveGi-coupledreceptoronSwiss3T3
ﬁbroblasts [7, 8] or activating p38 protein kinase pathway
in mouse lung capillary endothelial cells [9]. The approach
of Luppi et al. detected C-peptide in early endosomes which
can be signalling station in the cell, though C-peptide might
achieve its cellular eﬀects [10].
There is a certain controversy regarding reported eﬀects
of the C-peptide. Its beneﬁcial eﬀects have been demonstrat-
edinlong-termcomplicationintype1diabetes.Substitution
of C-peptide in type 1 diabetes improves glomerular hyper-
ﬁltration, hypertrophy, and proteinuria [11–14]. In contrast
to this, C-peptide in type 2 diabetes shows proinﬂammatory
and proatherogenic eﬀects [15, 16]. The aim of this paper
focuses on the proinﬂammatory eﬀects of C-peptide and its
potential importance in atherosclerosis in diabetic subjects.
2. Atherosclerosis Is an Inﬂammatory Disease
Atherosclerotic lesions are molecular and cellular responses
in the vessel wall that have been described as inﬂammatory
disease [17]. Endothelial dysfunction is an early event in
atherosclerosis and an important feature of glucose intoler-
ance, diabetes, obesity, and dyslipidemia, as well as a major
component of cardiovascular disorders, including hyperten-
sion and atherosclerosic diseases [18]. The atherosclerotic
plaque consists of necrotic core, calciﬁed regions, foam
cells with accumulated lipids, inﬂamed smooth muscle cells,
endothelial cells, lymphocytes, and leukocytes [17]. Mini-
mally oxidised LDL in blood can release bioactive phospho-
lipids that can activate vascular endothelial cells to express
leukocyte adhesion molecules, such as vascular cell adhesion2 Mediators of Inﬂammation
molecule-1 (VCAM-1) or intercellular adhesion molecule-1
(ICAM-1) [19]. Highly oxidised LDL can be recognised by
monocytes scavenger receptor to be transformed into foam
cells (Figure 1). Minimally oxidised LDL-induced expression
of adhesion molecules induces initial step in atherosclerosis,
leukocyte recruitment, and rolling on the endothelium.
Moreover, activated endothelium expresses selectins, mono-
cyte chemoattractant protein-1 (MCP-1), RANTES, and
fractalkine, which allow leukocyte adherence to the endothe-
lium [20]. Chemokines are small proteins, and their primary
function is activation of speciﬁc pertusis-toxin sensitive G-
protein-coupled receptors, which results in migration of
inﬂammatory cells [21]. Monocytes and T lymphocytes are
migrating into the intima of the vessel wall. Monocytes
are expressing scavenger receptor and toll-like receptor,
which mediate diﬀerentiation into foam cells. These cells in
additionplaycentralroleinatheroscleroticplaqueformation
[22, 23]. In atheroma activated macrophages release IL-
6, TNFα, MIF, and other proinﬂammatory cytokines and
chemokines as well as nitric oxide. This proinﬂammatory
response promotes replication of smooth muscle cells from
the media and formation of extracellular matrix [17].
T lymphocytes are entering the subendothelial space as
na¨ ıve T0 cells. Family of T cell chemoattractants such as IP-
10 can in the same way regulate lymphocyte recruitment
into the atheroma [24]. Smooth muscle cells are producing
extracellular matrix within the vessel wall and in response
to atherogenic stimuli they can modify the type of matrix
produced.Further,thetypeofmatrixaﬀectsthelipidcontent
of the plaque and the proliferative index of the cells attached
to the plaque [25]. T lymphocytes release interferon-γ (IFN-
γ) into the plaque, which might block the collagen synthesis
in SMC and decrease their ability to renew the collagen. Deg-
radation of extracellular matrix allows penetration of SMCs
through elastic laminae and enables plaque to grow [26]. Ac-
tivated macrophages secrete proteolytic enzymes and matrix
metalloproteinases, and that can lead to degradation of the
matrix complex of the plaque and destabilisation of the
atheromawithincreasedriskforplaqueruptureandcanlead
to acute clinical events such as myocardial infarction and
stroke [27].
2.1. Proinﬂammatory In Vitro Eﬀects of C-Peptide. Individu-
alswithdiabeteshaveincreasedriskofcoronaryheartdisease
compared with nondiabetic individuals, and the risk of
cardiovascular deaths is as high as in nondiabetic individuals
with previous myocardial infarction [28].
Marx et al. reported deposition of C-peptide in the
subendothelial space in carotid artery in diabetic subjects
[15]. In some of the subjects, deposition of C-peptide was
foundinthemediaoftheartery.Incontrasttothis,innondi-
abetic patients deposition of C-peptide has not been found.
All the 21 subjects involved in the study had deposition of
C-peptide, with 77% of them also having inﬁltration of
monocytes and just 57% inﬁltration of T lymphocytes [15].
Marx and colleagues used these results to propose the hy-
pothesis that C-peptide may have chemotactic eﬀects on the
inﬂammatory cells and might have a role in atherosclerosis
(Figure 1). In vitro migration assays performed in modiﬁed
Boyden chambers reported that C-peptide induces migra-
tion of T lymphocytes and monocytes/macrophages in a
concentration-dependent manner. These eﬀects were similar
to those induced with monocyte chemokine MCP-1 or
T-lymphocyte chemokine RANTES [15, 29]. In addition,
checkerboard analysis in the same study showed that C-
peptide induces chemotaxis rather than chemokinesis [29].
Also there are no migratory eﬀects of C-peptide on B cells or
neutrophils [30]. C-peptide stimulates speciﬁc intracellular
signalling pathways in diﬀerent cell types [8, 9, 31], for
example, Na+/K+ATP-ase [5, 32] ERK kinase, PI-3 Kinase
[8, 29, 32, 33], and AKT [8, 32, 33]. In T lymphocyte or
in monocytes, C-peptide mediates its chemotactic activity
through an as-of-yet- unidentiﬁed pertussis toxin sensitive
G-protein-coupled receptor with subsequent downstream
activation of PI3-kinase γ. Our experiments demonstrated
that a speciﬁc inhibitor of Src-kinase, PP2, in addition to
transfection of Src siRNA, abolished C-peptide-induced T
lymphocytemigration,suggestingthatC-peptidealsosignals
through this pathway. Besides, experiments showed that PI-
3 kinase activation leads to the involvement of small Rho-
GTPases,likeRhoA,Rac-1,andCdc42inthesecells.Further-
more in CD4-positive lymphocytes, C-peptide stimulates
phosphorylation of PAK (p21-activated kinase), LIMK (LIM
domain-containing protein kinase), and coﬁlin downstream
of Rac-1 and Cdc42, leading to coﬁlin inactivation and
actinﬁlamentstabilization.Alternatively,C-peptideactivates
ROCK(Rhokinase)andMLC(myosinlightchain)phospho-
rylation downstream of RhoA, thereby stimulating myosin-
mediated cell contraction [30]. These data supported an
active role of C-peptide in chemotaxis of inﬂammatory cells.
C-peptidehasaneﬀectonincreasedmicrovascularblood
ﬂow in patients with type 1 diabetes [34]. Some studies sug-
gestdirectroleofendogenousinsulinandC-peptideinamel-
ioration of endothelial dysfunction [35]. Additionally, C-
peptide increases nitric oxide (NO) production through
ERK-dependentupregulationofendothelialnitricoxidesyn-
thase (eNOS) gene transcription [36].
In addition, C-peptide positively inﬂuences the expres-
sion of CD34 scavenger receptor in human THP-1 mono-
cytes. These data suggest that C-peptide may also promote
the diﬀerentiation of monocyte/macrophages towards foam
cells, thus representing another potential proatherogenic
eﬀect of C-peptide [37].
FurthereﬀectsofC-peptidehavebeenin vestigatedonthe
smooth muscle cells, which are important for the develop-
ment of atherosclerosis. Stimulation with C-peptide induced
proliferation of smooth muscle cells in concentration-de-
pendent manner. Walcher and colleagues showed signiﬁ-
cantly higher production of KI-67 nuclear protein and 3[H]-
thymidine incorporation in vascular cells stimulated with
C-peptide. This proliferation was similar to those induced
by platelet-derived growth factor (PDGF) [33]. Additionally,
C-peptide stimulation induces phosphorylation of protein
tyrosine kinase Src and PI-3 kinase, which leads to down-
stream stimulation of MAP ERK1/2 [33]. It is already
demonstrated that activation of ERK1/2 is a crucial step in































Figure 1: In insulin resistance and early type 2 diabetes insulin levels are increased in circulation. C-peptide levels in blood are increased in
equimolar concentration with insulin. C-peptide deposits in subendothelial place in the vessel wall. Deposition is followed by chemotactic
eﬀect of C-peptide on the inﬂammatory cells. It induces migration of monocyte/macrophages and T lymphocytes into the vessel wall.
C-peptide has also an eﬀect on the proliferation of smooth muscle cells from the media.
control of VSMC proliferation by extracellular stimuli takes
place in mid- to late G1 phase of the cell cycle, where D-type
cyclins promote G1- to S-phase transition by leading to Rb
phosphorylation [39, 40]. Our data showed an increase in
cyclin D1 expression, whereas Rb phosphorylation suggested
that C-peptide acts via similar signalling pathways [33].
C-peptide mitogenic eﬀects have been detected in other
cell types, like endothelial cells, HEK293 cells, and chon-
drocytes. When endothelial cells were exposed to C-peptide,
a signiﬁcant increase in cell number of 40% was observed
[41]( Figure 1). Another group has found that C-peptide
stimulates rRNA synthesis, suggesting that the peptide can
have proliferative eﬀects and induces expression of 47S in
HCS-2/8 chondrocytes derived from a human chondrosar-
coma. After 72 hours of exposure to C-peptide, cell counting
under a phase contrast microscope and measurement with
a cell proliferation kit and BrdUrd staining established that
C-peptide exerts proliferative eﬀects on chondrocytes [42].
3. Proinﬂammatory In Vivo
Effects of C-Peptide
Observational data from previous studies showed deposi-
tion of C-peptide in intima of the carotid artery in diabetic
individuals [15]. Further, these data showed that C-peptide
induces chemotaxis of inﬂammatory cells in vitro and
activation of intracellular signalling pathways [29, 30]. These
observations needed in vivo experimental model to explore
eﬀects of C-peptide in onset of atherosclerosis. To test this
hypothesis we applied ApoE-deﬁcient mouse model. The
animals were divided into two groups. C-peptide group
numbered 18, and placebo 17 mice per group [16]. After
subcutaneous injections (200nmol/injection) of dissolved
peptide we identify that C-peptide levels in blood increased
4- to 5-fold compared to basal levels (12.9 ± 1.8nmol/L
compared with 2.7 ± 0.8nmol/L; C-peptide versus placebo;
P<0.05). Simultaneously mice were put on the western
type diet to trigger atherosclerosis. Immunohistochemical
analysis of the aortic arch showed deposition of C-peptide
intheearlyatheroscleroticplaques.Computer-assistedimage
quantiﬁcation revealed signiﬁcantly higher deposition of C-
peptide in treated mice, compared to placebo one (2.1 ±
0.4v e r s u s0 .8 ± 0.1% positive area; P<0.01) treated
with water (Figure 2). Similar results were obtained in
the aortic root (data not shown). After 12 weeks of C-
peptide or water sc injections body weight and lipids (total
cholesterol, triglyceride, high density lipoprotein, and low
density lipoprotein) did not diﬀer between the two treated4 Mediators of Inﬂammation
groups. In addition, glucose and insulin levels showed no
diﬀerences between groups.
Deposition of C-peptide was followed with increased
inﬁltration of inﬂammatory cells such as monocytes/macro-
phages in the aortic arch. Moreover, higher deposition of
inﬂammatory cells has been detected in the aortic root (data
not shown). Colocalization of C-peptide with inﬂammatory
cells was already demonstrated in early atherosclerotic pla-
ques of diabetic patients [15]. In contrast to this it has been
revealed that C-peptide demonstrates antithrombotic eﬀects
in vivo. Administration of C-peptide in high doses caused
delay in arteriolar and venular thrombus growth in normal
and diabetic mice [43].
Wealreadyknowthatdiabetesacceleratessmoothmuscle
cell proliferation in atherosclerotic lesions and that it cor-
relates with insulin levels [44]. In a study by Walcher et al.,
authors revealed that the C-peptide acts as a mitogen on the
human and rat arterial vascular smooth muscle cells in-vitro
[33]. Staining for α-actin (Figure 2) in animal model has
shown signiﬁcantly higher content of smooth muscle cells in
C-peptide-treated group (C-peptide versus placebo: 4.8±0.6
versus 2.4 ± 0.7% positive area; P<0.01) as well as a trend
t o w a r d sm o r eK I - 6 7p r o l i f e r a t e dc e l l si nC - p e p t i d e - t r e a t e d
group.
C-peptide had signiﬁcantly higher deposition of lipids
in aortic arch compared with placebo. Lipid deposition in
en face preparations of the abdominal and thoracic aorta in
C-peptide-treated mice did not reach statistical signiﬁcance
compared to placebo mice (C-peptide versus placebo: 5.64±
0.69% versus 3.98 ± 0.5%; P = 0.07) [16]. A possible ex-
planation could be that C-peptide proinﬂammatory eﬀects
obtained in the ApoE-deﬁcient animals were on top of a
high-cholesterol diet. Initial aim of this study was to detect
deposition of C-peptide in the vessel wall in an animal mod-
el without distinguishing metabolic eﬀects. In the future it
would be interesting to use a model of diabetes and ath-
erosclerosisprone mice fed with high-cholesterol diet such
as ob/ob or LDL−/− mice. Furthermore, nothing is known
about C-peptide eﬀects on plaque vulnerability or produc-
tion of metalloproteinases. Future studies should answer
these questions.
4. Discussion
C-peptide is by now identiﬁed as a biologically active
substance. Many studies initiate C-peptide as an active
peptidehormonewithimportantphysiologicaleﬀects,which
aﬀects renal, neuronal, and microvascular functions in
patients with diabetes [45–48]. C-peptide increases capil-
lary blood ﬂow in type 1 diabetic patients [49], through
increasedinﬂuxofCa2+ intoendothelialcells,whichfacilitate
release of NO from the endothelium. Many studies have
demonstrated beneﬁcial eﬀects of C-peptide on the long-
term complications in type 1 diabetic patients. This could
have an important therapeutic implication [11, 12]. For
example, decreased blood ﬂow in the extremities might
be prevented by C-peptide [50]. Moreover, improvements
of endoneurial blood ﬂow and axonal swelling have been
also demonstrated by introduction of C-peptide [51]. In
numerous studies of type 1 diabetes glomerular hyperﬁl-
tration, hypertrophy, and proteinuria have been reduced
by C-peptide [13, 14, 52]. C-peptide treatment improves
sensory nerve function in early stage of type 1 diabetic
neuropathy [47]. The eﬀects of C-peptide on type 2 diabetes
as well as on the cell proliferation and apoptosis are very
controversial at present. Levels of inﬂammation in type 1
and type 2 diabetes are still unknown, but it has been
found that plasma levels of IL-6 correlate with C-peptide
levels and insulin sensitivity [53]. The metabolic syndrome,
prediabetes, and type 2 diabetes mellitus accelerate vascular
disease and increase development of the disease [54]. At
the moment the reasons for the increased predisposition
and progression of atherosclerosis in patients with diabetes
are unknown. In vivo model from Vasic et al.[16] showed
increased deposition of C-peptide in early atherosclerotic
lesions in ApoE-deﬁcient mice. C-peptide deposition was
followed by recruitment of inﬂammatory cells into the vessel
wall and increased inﬁltration of monocytes/macrophages
as well as increased proliferation of smooth muscle cells.
These results are also in agreement with in vitro data of
Swiss 3T3 ﬁbroblasts, where C-peptide has been shown to
activate PI-3 kinase [8] as well as increased expression of
PPAR-γ regulated CD36 scavenger receptor in human THP-
1 monocytes by C-peptide. These results recommend that
C-peptide in addition to these eﬀects might promote the
diﬀerentiation of monocyte/macrophages into foam cells
[37]. Our study showed no diﬀerences in E-selectin and
ICAM-1 levels as well as levels of the inﬂammatory markers
such as TNFα and soluble IL-6. An explanation could
be that C-peptide was used in this model on top of the
hypercholesterinemic diet. But these data are in contrast to
several ﬁndings in which C-peptide has anti-inﬂammatory
eﬀects and reduced upregulation of cell adhesion molecules
under inﬂammatory conditions [55, 56]. In mice with
endotoxicshock,C-peptidetreatmentimprovedsurvivalrate
and reduced plasma levels of tumour necrosis factor-alpha
(TNFα), macrophage inﬂammatory protein-1 alpha, and
monocyte chemoattractant protein-1 [57].
We already know that the smooth muscle cells and their
secreted products are the main components of advanced
atherosclerotic lesions [58]. C-peptide deposition was also
found in the media in diabetic patients. Moreover, C-
peptideinducedproliferationofsmoothmusclecellsinvitro,
therefore potentially promoting both the development of
atherosclerotic lesions and neointima formation after coro-
nary intervention [33]. After vascular injury, smooth muscle
cells start to proliferate and migrate into the developing
neointima. They develop into the major cellular substrate
of the restenotic tissue [59]. In vivo studies showed that
downregulation of ERK1/2 inhibits early smooth muscle cell
proliferation and neointimal thickening in response to arte-
rial injury [60]. In smooth muscle cells C-peptide induces
ERK1/2 signalling. Data obtained from ApoE-deﬁcient mice
demonstrated signiﬁcantly higher content of smooth muscle
cells in mouse aortic arch, which was followed with higher
deposition of lipids in early atherosclerotic lesions in mice

















Figure 2: Increased levels of C-peptide in ApoE-deﬁcient mice were established by subcutaneously injections of C-peptide. C-peptide was
administrated two times daily by subcutaneous injections for 12 weeks. Deposition of C-peptide in aortic arch has been investigated in mice
treated with C-peptide and control mice. Increased deposition of C-peptide in treated mice leads to increased inﬁltration of inﬂammatory
cells (monocytes/macrophages), increased proliferation of smooth muscle cells from the media, and increased deposition of lipids in aortic
arch assessed by immunohistochemistry.6 Mediators of Inﬂammation
contrast to this, in vitro results by Kobayashi revealed
that human C-peptide at high concentrations (100nmol)
suppresses the growth of rat SMCs [61]. A recent study by
Cifarelli demonstrated that C-peptide signiﬁcantly decreases
caspase-3 activity and upregulated production of the anti-
apoptoticfactorB-cellCLL/lymphoma2(BCL-2)[62].Anti-
inﬂammatoryeﬀectsofC-peptidewereobservedinthestudy
by Chima et al., where C-peptide has been shown to react as
inhibitoroflunginﬂammationfollowinghemorrhagicshock
[63].
Conﬂicting data could be possibly explained with the
existence of diﬀerent circulating insulin and C-peptide levels
in diabetes type 2 and diabetes type 1. Most of the studies
suggesting anti-inﬂammatory and antiapoptotic eﬀects of
C-peptide performed their experiments on the diverse cell
types simulating type 1 diabetes with high glucose levels
and low levels of C-peptide where its substitution was
beneﬁcial. In regard to this, C-peptide protects endothelial
cells from apoptosis and inﬂammation triggered by high
glucose conditions [62]. The situation canbe totally diﬀerent
in patients with insulin resistance and type 2 diabetes where
high levels of C-peptide could have opposite eﬀects.
ArecentstudysuggeststhatbasalC-peptidelevelsintype
2diabetes relatedtometabolicsyndromecorrelatetointima-
media thickness and C-peptide could be used as surrogate
marker of subclinical atherosclerosis [64]. Moreover, Lindahl
and colleagues showed that C-peptide stimulates the prolif-
eration of chondrocytes and HEK-293 cells. This regulation
of ribosomal RNA means that C-peptide has growth factor
activity [42].
In the last few decades C-peptide is presented as an active
peptide with diverse eﬀects. Diﬀerent eﬀects in type 1 and
type 2 diabetes seem to be tissue and cell speciﬁc. Further
work is needed to identify C-peptide receptor and elucidate
mechanisms by which C-peptide modulates cell signalling in
diﬀerent cell types.
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